The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
In India, 'Mounjaro brides' are using weight-loss injections as part of pre-wedding rituals, driven by intense societal expectations. Clinics like Klarity Skin Clinic offer specialized packages, while doctors report a surge in queries from brides and grooms. This trend highlights both the drugs' popularity and the need for medical supervision.
A 27-year-old man from Wigan is being hunted by police after failing to appear in court on charges of stealing over £12,000 worth of Mounjaro weight loss injections from his workplace. The theft highlights the skyrocketing demand for this GLP-1 medication used for type 2 diabetes and appetite control. Understand the case details and what makes Mounjaro so sought after.
Vice President JD Vance appeared noticeably slimmer in a recent interview with Benny Johnson, igniting Ozempic rumors across X. Netizens speculate on the popular weight-loss drug amid past denials and critic backlash. While no confirmation exists, the buzz highlights Ozempic's role in metabolic health conversations.
Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.
Emcure Pharmaceuticals has reduced the price of its semaglutide injection Poviztra by 55% for the starting dose, now at ₹3,999 per month. This move, in partnership with Novo Nordisk, follows recent price slashes on Wegovy and Ozempic and the launch of Indian generics. It aims to tackle India's growing obesity epidemic affecting over 600 million adults.
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
Emcure Pharmaceuticals has dramatically reduced Poviztra prices by 55% for the starting dose, fueling a semaglutide price war in India after patent exclusivity lapsed. This move positions the branded pen injector competitively against generics priced as low as Rs 1,200-1,500 per month. With obesity rates rising, these changes could widen access to this proven weight-management therapy.
GLP-1 medications like Ozempic are no longer just a healthcare trend—they're transforming retail demand patterns. Clootrack's study of 95,854 consumer conversations uncovers four key purchase rhythms in grocery, apparel, beauty, and fitness that traditional sales data misses. Retailers ignoring these weekly cycles risk misaligned promotions and lost opportunities.
